BRPI0412212A - uso da dapsona como neuroprotetor no infarto cerebral - Google Patents

uso da dapsona como neuroprotetor no infarto cerebral

Info

Publication number
BRPI0412212A
BRPI0412212A BRPI0412212-7A BRPI0412212A BRPI0412212A BR PI0412212 A BRPI0412212 A BR PI0412212A BR PI0412212 A BRPI0412212 A BR PI0412212A BR PI0412212 A BRPI0412212 A BR PI0412212A
Authority
BR
Brazil
Prior art keywords
dapsone
cerebral infarction
neuroprotective agent
stroke
brain stroke
Prior art date
Application number
BRPI0412212-7A
Other languages
English (en)
Inventor
Luis Camillo Rios Casta Eda
Marina Altagracia Martinez
Juan Nader Kawachi
Jaime Kravzov Jinich
Original Assignee
Univ Autonoma Metropolitana
Inst Nac De Neurologia Y Neuro
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Autonoma Metropolitana, Inst Nac De Neurologia Y Neuro filed Critical Univ Autonoma Metropolitana
Publication of BRPI0412212A publication Critical patent/BRPI0412212A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Mobile Radio Communication Systems (AREA)

Abstract

"USO DA DAPSONA COMO NEUROPROTETOR NO INFARTO CEREBRAL". A presente invenção tem por objetivo demonstrar o uso da dapsona como o primeiro tratamento eficaz contra as conseqüências incapacitantes associadas com o infarto cerebral nestes pacientes; a dapsona foi avaliada como neuroprotetor, no modelo de infarto cerebral produzido pela oclusão da artéria cerebral média nos ratos e em pacientes que sofreram um infarto cerebral agudo por trombo-embolismo; em ambos os estudos, a dapsona demonstrou uma redução dentre 70 e 90% das conseqüências adversas que se apresentam como conseqüência do infarto.
BRPI0412212-7A 2003-07-22 2004-03-16 uso da dapsona como neuroprotetor no infarto cerebral BRPI0412212A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
MXPA03006549A MXPA03006549A (es) 2003-07-22 2003-07-22 Uso de la dapsona como neuroprotector en el infarto cerebral.
PCT/MX2004/000018 WO2005007239A1 (es) 2003-07-22 2004-03-16 Uso de la dapsona como neuroprotector en el infarto cerebral

Publications (1)

Publication Number Publication Date
BRPI0412212A true BRPI0412212A (pt) 2006-08-22

Family

ID=34075071

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0412212-7A BRPI0412212A (pt) 2003-07-22 2004-03-16 uso da dapsona como neuroprotetor no infarto cerebral

Country Status (15)

Country Link
US (1) US8268893B2 (pt)
EP (1) EP1655055B1 (pt)
JP (1) JP5452844B2 (pt)
CN (1) CN100500246C (pt)
AT (1) ATE362783T1 (pt)
BR (1) BRPI0412212A (pt)
CA (1) CA2533181C (pt)
DE (1) DE602004006633T2 (pt)
EA (1) EA012174B1 (pt)
EC (1) ECSP066316A (pt)
ES (1) ES2287713T3 (pt)
HK (1) HK1098086A1 (pt)
MX (1) MXPA03006549A (pt)
PT (1) PT1655055E (pt)
WO (1) WO2005007239A1 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2009004635A (es) * 2009-04-29 2010-10-29 Univ Autonoma Metropolitana Formas farmaceúticas solubles de la n,n´-diamino-difenilsulfona para su uso óptimo en el tratamiento de diversas enfermedades.
KR101875705B1 (ko) * 2011-12-07 2018-07-06 삼성전자주식회사 디아미노디페닐술폰을 포함하는 근육 소모 관련 질환의 예방 또는 치료용 약학적 조성물
CN104177610A (zh) * 2013-05-27 2014-12-03 韩文毅 一种非线性的聚合物及其制备和用途
CN104177611A (zh) * 2013-05-27 2014-12-03 韩文毅 一种非线性的聚合物及其制备和用途
CN104069091A (zh) * 2014-07-09 2014-10-01 崔德华 氨苯砜在保护血脑屏障完整性中的应用
KR20160047318A (ko) * 2014-10-22 2016-05-02 삼성전자주식회사 다프손을 포함하는, 개체의 부위에서 혈관신생을 자극시키기 위한 조성물 및 그의 용도
KR20200107899A (ko) * 2019-11-16 2020-09-16 이종훈 알츠하이머병 혹은 뇌졸중의 뉴로인플라마섬의 치료제로서 디디에스 혹은 그 유도체

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5532219A (en) * 1991-04-23 1996-07-02 The University Of British Columbia Dapsone and promin for the treatment of dementia
CN1309659A (zh) * 1998-07-15 2001-08-22 哈桑·朱马 有机磷化合物及其用途
GB2362101A (en) * 2000-05-12 2001-11-14 Astrazeneca Ab Treatment of chronic obstructive pulmonary disease

Also Published As

Publication number Publication date
DE602004006633T2 (de) 2008-01-31
HK1098086A1 (en) 2007-07-13
US20100063159A1 (en) 2010-03-11
WO2005007239B1 (es) 2005-05-06
ES2287713T3 (es) 2007-12-16
EA012174B1 (ru) 2009-08-28
CN1852749A (zh) 2006-10-25
CA2533181A1 (en) 2005-01-27
ECSP066316A (es) 2006-10-25
DE602004006633D1 (de) 2007-07-05
CA2533181C (en) 2012-08-07
MXPA03006549A (es) 2004-03-18
JP5452844B2 (ja) 2014-03-26
EA200600272A1 (ru) 2006-10-27
ATE362783T1 (de) 2007-06-15
JP2006528175A (ja) 2006-12-14
US8268893B2 (en) 2012-09-18
PT1655055E (pt) 2007-08-31
EP1655055A1 (en) 2006-05-10
EP1655055B1 (en) 2007-05-23
WO2005007239A1 (es) 2005-01-27
CN100500246C (zh) 2009-06-17

Similar Documents

Publication Publication Date Title
ATE535236T1 (de) Therapeutische strategien für die prävention und behandlung der alzheimer-krankheit
DE60314633D1 (de) Substituierte 1,3-diphenylprop-2-en-1-on derivate, deren herstellung und anwendungen
BRPI0506305A (pt) artigos e métodos de tratamento da pele
ECSP066316A (es) Uso de la dapsona como neuroprotector en el infarto cerebral
IL172396A0 (en) Replikin peptides and uses thereof
WO2006118771A3 (en) Treatment of teeth by aligners
WO2007012061A3 (en) Prevention and treatment of synucleinopathic and amyloidogenic disease
EP1765388B8 (de) Kombinationstherapie zur vorbeugung oder behandlung der alzheimerschen erkrankung sowie set hierfür
WO2006020581A3 (en) Prevention and treatment of synucleinopathic and amyloidogenic disease
BRPI0316438C1 (pt) uso de eritropoietina em doenças cardíacas
IL177787A0 (en) 1-aminovyclohexane derivatives for the treatment of agitation and other behavioral disorders, especially those associated with alzheimer's disease
DE602006004009D1 (de) 3,11b-cis-dihydrotetrabanezin zur behandlung von schizophrenie und anderen psychosen
BRPI0407662A (pt) derivados do ácido 1-fenilalcanocarboxìlico para o tratamento de doenças neurodegenerativas
ATE319439T1 (de) Mittel zur behandlung von erkrankungen des tracheo-bronchialtraktes, insbesondere der copd
ATE437988T1 (de) Neues imprägnierverfahren einer textiloberfläche
IT1305313B1 (it) 3,4 - diidro- 6- benzil-4-oxopirimidine sostituite e relativo processodi produzione e impiego nella terapia delle infezioni da hiv-1.
HRP20070291T3 (en) Pharmaceutical composition comprising a zinc-hyaluronate complex for the treatment of multiple sclerosis
ATE552251T1 (de) Thiophen- und furanverbindungen
WO2002099422A3 (en) Individualization of therapy with alzheimer's disease agents
ATE345135T1 (de) Tropan-derivate mit dopamin-wiederaufnahme-hemmer-wirkung für die behandlung von ischämischen erkrankungen
BRPI0411427A (pt) formulações de agentes antiinflamatórios não-esteróides para o tratamento de angiogênese ocular patológica
WO2004006900A3 (en) Sulphydryl compounds in combination with sulphone or sulphnamide conpounds for use in microbial inflammatory diseases
JP2006501269A5 (pt)
CY1110278T1 (el) Μεθοδος διαλογης παραγοντων ικανων να θεραπευουν την παχυσαρκια
EP1578353A4 (en) METHODS OF USE AND COMPOSITIONS FOR THE DIAGNOSIS AND TREATMENT OF INFECTION DISEASES

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: PARA.INT.CI. A61K 31/135, A61K 31/136, A61P 25/00, A61P 9/10

Ipc: A61K 31/135 (2011.01), A61K 31/136 (2011.01), A61P

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 13A ANUIDADE.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]